Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study

Journal of Cancer Research and Clinical Oncology

Volumn 144, Issue 5, 2018, Pages 901-908

  Abdel Rahman, Omar ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

ALBI; BMI; HCC; Prognosis; Sorafenib

Indexed keywords

ADEFOVIR; ALPHA FETOPROTEIN; ENTECAVIR; LAMIVUDINE; SORAFENIB; SUNITINIB; TENOFOVIR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PYRROLE DERIVATIVE;

ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COHORT ANALYSIS; KAPLAN MEIER METHOD; LIVER TUMOR; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; NIACINAMIDE; OUTCOME ASSESSMENT (HEALTH CARE); PHENYLUREA COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PYRROLES;

EID: 85042088471     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-018-2610-z     Document Type: Article

References (23)

1. Abdel-Rahman O (2017a) Assessment of the discriminating value of the 8th AJCC stage grouping for hepatocellular carcinoma. HPB (Oxford)
2. Abdel-Rahman O (2017b) Role of liver-directed local tumor therapy in the management of hepatocellular carcinoma with extrahepatic metastases: a SEER database analysis. Expert Rev Gastroenterol Hepatol 11(2):183–189
3. Abdel-Rahman O, Elsayed Z (2017) External beam radiotherapy for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev (3)
4. Abdel-Rahman O, Fouad M (2014) Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev Oncol Hematol 91(1):1–8
5. Abdel-Rahman O, Lamarca A (2017) Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. Expert Rev Gastroenterol Hepatol 11(1):75–83
6. Bruix J, Cheng A, Kang Y, Tsao C, Qin S, Lentini G et al (2009) Effect of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ECOG performance status (ECOG PS) on outcome in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib: Analysis of two phase III, randomized, double-blind trials. J Clin Oncol 27(15S):4580-
7. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34
8. Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX (2016) Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer 122(22):3430–3446
9. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359-86
10. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol 33(6):550–558
11. Lamarca A, Abdel-Rahman O, Salu I, McNamara MG, Valle JW, Hubner RA (2016) Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. Clin Transl Oncol
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390
13. Lue A, Serrano MT, Bustamante FJ, Inarrairaegui M, Arenas JI, Testillano M et al (2017) Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. Oncotarget 8(61):103077–103086
14. Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP et al (2016) Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol 65(6):1140–1147
15. Mir O, Coriat R, Blanchet B, Durand J-P, Boudou-Rouquette P, Michels J et al (2012) Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 7(5):e37563
16. Mittal S, El-Serag HB (2013) Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 47(Suppl):S2–S6
17. Nada Y, Rashad N, Eissa M, Ghonaim A, Farag K, Saadawi I et al (2017) Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. Expert Rev Gastroenterol Hepatol 1–9
18. Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H et al (2017) Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis. J Cancer 8(3):378–387
19. Oweira H, Helbling D, Petrausch U et al (2017) Early stage Hepatocellular carcinoma in the elderly: a SEER database analysis. J Geriatric Oncol (in press)
20. Parikh ND, Marshall VD, Singal AG, Nathan H, Lok AS, Balkrishnan R et al (2017) Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: an analysis of the SEER-Medicare database. Hepatology 65(1):122–133
21. Qin S, Yang T, Tak W, Yu S, Tsao C, Kim J et al (2009) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Asia-Pacific (AP) trial subgroup analyses by baseline transaminase (ALT/AST)/α-fetoprotein (AFP) levels. J Clin Oncol 27(15S):4590-
22. Raoul J, Craxi A, Porta C, Lentini G, Nadel A, Voliotis D et al (2009) Impact of lymph node metastases on outcome following treatment with sorafenib in patients with hepatocellular carcinoma (HCC): subset analysis from the phase III SHARP trial. J Clin Oncol 27(15S):e15547
23. Yang T, Qin S, Tak W, Yu S, Tsao C, Kim J et al (2009) Impact of prior surgical resection with curative intent on the efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): subset analysis of the Asia-Pacific (AP) study. J Clin Oncol 27(15S):e15518